Tesamorelin

What it is

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). Like sermorelin and CJC-1295 it stimulates the pituitary to release the body’s own growth hormone, but structural modifications make it more resistant to breakdown. Unlike the other peptides in this group, tesamorelin was developed as a conventional pharmaceutical, tested in large trials, and brought to market.

What it’s approved or studied for

Tesamorelin is FDA-approved (2010) as Egrifta for one specific indication: reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy — a condition in which fat accumulates around the abdominal organs. It is the only medication approved in the U.S. for that purpose, and it remains marketed (Egrifta SV, and the 2025 reformulation Egrifta WR). Everything outside that indication — general weight loss, “anti-aging,” bodybuilding — is off-label.

What human evidence exists

For its approved use the evidence is strong. Two large phase-3, randomized, placebo-controlled trials showed roughly a 15% reduction in visceral adipose tissue over 26 weeks versus placebo, with accompanying lipid improvements (Grade A for VAT reduction, Grade B for triglycerides). Later randomized work in people with HIV also suggests liver-fat reduction (Grade C, not approved). Critically, this evidence is HIV-specific: there is no adequate trial showing it helps people without HIV-associated lipodystrophy (Grade U).

The major unknowns

The main open question is generalizability — the approved benefit was measured in a particular patient population, and it should not be assumed to transfer to healthy adults seeking fat loss or anti-aging effects. Long-term safety beyond the trial periods, and the significance of the IGF-1 rise it produces, continue to be monitored.

Most important safety considerations

Tesamorelin raises IGF-1 and can worsen glucose control and cause fluid retention; joint pain and injection-site reactions are common. It is contraindicated in active malignancy, in pregnancy, and with disruption of the hypothalamic-pituitary axis. It is prohibited in sport under WADA’s S2 category. Even though it is FDA-approved, it is approved for a narrow indication and should be used only under medical supervision — this page is a research summary, not medical advice.